Related Experiment Video
Updated: Jul 10, 2026

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia
Published on: June 28, 2018
Nosocomial Acinetobacter pneumonia
Carlos M Luna1, Patricia K Aruj
1Department of Internal Medicine, Pulmonary Diseases Division, Hospital de Clínicas, Universidad de Buenos Aires, Argentina. cymluna@advancedsl.com.ar
Abstract:
Acinetobacter spp. (A. baumannii is the prevalent genomic species, but others may cause infection) has become an increasingly important cause of nosocomial pneumonia, particularly in mechanically ventilated patients (VAP). This organism has intrinsic resistance to some antimicrobials but easily acquires resistance to many others; Acinetobacter spp. can survive for long periods of time in the environment. All of these characteristics have contributed to protracted outbreaks associated with significant morbidity and mortality. High rates of colonization are found in debilitated hospitalized patients. Infecting or colonizing organisms in nosocomial infections are more likely to be from cross-transmission or from the hospital environment than from endogenous sources. VAP caused by Acinetobacter spp. is emerging as a prominent hospital complication. The incidence of this microorganism varies from site to site, but it is the second commonest aetiological agent among the gram-negative bacteria. Longer periods of hospitalization, longer time on mechanical ventilation and prior use of antibiotics are the recognized factors increasing the risk of VAP due to Acinetobacter spp. Treatment needs to clearly differentiate infection from colonization, and the agents with the most antimicrobial activity are imipenem/cilastatin, amikacin, colistin, ampicillin/sulbactam and tigecycline. Monotherapy can be adequate if the patient does not have significant comorbidities. Infection control procedures have a major role to play in preventing transmission of this microorganism. Emphasis on initial control measures should, however, be on strict isolation of infected or colonized patients to limit dissemination of outbreak strains in the environment. The variety of potential sources of contamination with Acinetobacter spp. in the hospital environment makes control of these outbreaks one of the more difficult challenges. Persistence of Acinetobacter spp. in the environment provides ample opportunities for contamination of patients and staff and may explain continuing long-term outbreaks.
Insights
Acinetobacter spp. causes hospital-acquired pneumonia, especially in ventilated patients, due to its resistance and environmental persistence. Strict infection control and appropriate antibiotic treatment are crucial for managing outbreaks.
Area of Science:
- Medical Microbiology
- Infectious Diseases
- Hospital Epidemiology
Background:
- Acinetobacter spp., particularly A. baumannii, is a significant cause of nosocomial pneumonia in mechanically ventilated patients.
- This bacterium exhibits intrinsic and acquired antimicrobial resistance and environmental persistence, leading to difficult-to-control outbreaks.
- Nosocomial infections with Acinetobacter spp. are often linked to cross-transmission from the hospital environment or staff, rather than endogenous sources.
Purpose of the Study:
- To highlight Acinetobacter spp. as a growing threat in hospital-acquired infections, particularly ventilator-associated pneumonia (VAP).
- To discuss the contributing factors, clinical implications, and effective management strategies for Acinetobacter spp. VAP.
- To emphasize the importance of infection control measures in preventing and managing outbreaks.
Main Methods:
- Literature review and synthesis of existing data on Acinetobacter spp. epidemiology, resistance patterns, and clinical impact.
- Analysis of risk factors associated with Acinetobacter spp. VAP, including hospitalization duration and prior antibiotic use.
- Review of current antimicrobial treatment options and infection control strategies.
Main Results:
- Acinetobacter spp. is the second most common Gram-negative cause of VAP, associated with high morbidity and mortality.
- Risk factors for Acinetobacter spp. VAP include prolonged hospitalization, mechanical ventilation, and prior antibiotic exposure.
- Effective antimicrobial agents include imipenem/cilastatin, amikacin, colistin, ampicillin/sulbactam, and tigecycline; monotherapy may suffice in uncomplicated cases.
Conclusions:
- Strict infection control measures, including patient isolation, are paramount to prevent Acinetobacter spp. transmission and control outbreaks.
- Differentiating between colonization and infection is critical for appropriate patient management.
- The environmental persistence of Acinetobacter spp. poses a continuous challenge for healthcare facilities, necessitating robust infection prevention programs.
Related Concept Videos
Pneumonia I: Introduction
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Atypical Pneumonia
Acute Pyelonephritis II: Diagnostic Studies and Management
Acute Pyelonephritis I: Introduction
Healthcare Associated Infections I: Iatrogenic, Exogenic and Endogenic
HAIs significantly increase the cost of health care. Extended stays in healthcare institutions, increased disability, increased costs of medications, including specialized antibiotics, and prolonged recovery times add to the patient's expenses and the healthcare institution and funding bodies. Common...
